The company could finally be ready to deliver on years of promise.
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
4d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
A sales partner offered a ray of hope that this company couldn't for itself.
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...
CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have ...
Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results